EICHORCondition: HIV Infections · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy (OBT) in HIV-1 infected infants, children, and adolescents.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program (Site ID: 4601) | La Jolla, California, United States | — |
| Miller Children's Hosp. Long Beach CA NICHD CRS (Site ID: 5093) | Long Beach, California, United States | — |
| David Geffen School of Medicine at UCLA NICHD CRS (Site ID: 5112) | Los Angeles, California, United States | — |
| Univ. of California San Francisco NICHD CRS (Site ID: 5091) | San Francisco, California, United States | — |
| Univ. of Colorado Denver NICHD CRS (Site ID: 5052) | Aurora, Colorado, United States | — |
| Howard Univ. Washington DC NICHD CRS (Site ID: 5044) | Washington D.C., District of Columbia, United States | — |
| South Florida CDTC Ft Lauderdale NICHD CRS (Site ID: 5055) | Fort Lauderdale, Florida, United States | — |
| USF - Tampa NICHD CRS (Site ID: 5018) | Tampa, Florida, United States | — |
| Rush Univ. Cook County Hosp. Chicago NICHD CRS (Site ID: 5083) | Chicago, Illinois, United States | — |
| Lurie Children's Hospital of Chicago (LCH) CRS (Site ID: 4001) | Chicago, Illinois, United States | — |
| Children's Hosp. of Boston NICHD CRS (Site ID: 5009) | Boston, Massachusetts, United States | — |
| Boston Medical Center Ped. HIV Program NICHD CRS (Site ID: 5011) | Boston, Massachusetts, United States | — |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01302847